Guo Zixuan, Tang Xinyue, Zhong Shuming, Chen Guanmao, Chen Pan, Chen Chao, Chen Ruoyi, Huang Li, Jia Yanbin, Wang Ying
Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou, China.
Department of Medical Imaging, Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Depress Anxiety. 2025 Aug 30;2025:1990117. doi: 10.1155/da/1990117. eCollection 2025.
The therapeutic effects of vortioxetine on mood and cognition have been documented in major depressive disorder (MDD). This study aims to examine whether vortioxetine can improve brain glymphatic system function and connections among functional brain networks and to explore the underlying relationships among these changes. A total of 34 patients with MDD and 41 healthy controls (HCs) were recruited in the study. All participants underwent mood and cognitive assessment, and diffusion tensor imaging (DTI) and resting-state functional MRI scans at baseline and 8-week follow-up. The DTI analysis along the perivascular space (DTI-ALPS) index, and functional connectivity (FC) were assessed. Cognitive assessment was conducted using the Chinese version of Measurement Consensus Cognitive Battery (MCCB). Correlation analysis was subsequently performed to explore underlying association among these indexes. Compared to HCs, patients with MDD showed decreased DTI-ALPS indexes at baseline; patients with MDD showed increased the default mode network (DMN) FC between the posterior cingulate cortex (PCC)-precuneus; patients with MDD displayed decreased attention/vigilance, verbal learning, visual learning, social cognition, and global cognition. Treatment with vortioxetine, patients with MDD displayed reduced depressive symptoms, increased DTI-ALPS indexes, decreased DMN FC, and improved attention/vigilance, verbal learning, visual learning, social cognition, and global cognition. Moreover, the increased DTI-ALPS indexes correlated with improved global cognition, and decreased DMN FC in MDD, respectively. The current study indicated vortioxetine improves glymphatic system function and brain connections within the DMN in MDD. Furthermore, the restoration of glymphatic function is linked to improved brain function and cognition. : ClinicalTrials.gov identifier: ChiCTR2200057820.
伏硫西汀对重度抑郁症（MDD）患者情绪和认知的治疗效果已有文献记载。本研究旨在探讨伏硫西汀是否能改善脑类淋巴系统功能以及功能性脑网络之间的连接，并探索这些变化之间的潜在关系。该研究共招募了34例MDD患者和41名健康对照者（HCs）。所有参与者在基线和8周随访时均接受了情绪和认知评估，以及扩散张量成像（DTI）和静息态功能磁共振成像扫描。评估了沿血管周围间隙的DTI分析（DTI-ALPS）指数和功能连接性（FC）。使用中文版的测量共识认知电池（MCCB）进行认知评估。随后进行相关性分析以探索这些指标之间的潜在关联。与HCs相比，MDD患者在基线时DTI-ALPS指数降低；MDD患者后扣带回皮质（PCC）-楔前叶之间的默认模式网络（DMN）FC增加；MDD患者的注意力/警觉性、言语学习、视觉学习、社会认知和整体认知下降。伏硫西汀治疗后，MDD患者的抑郁症状减轻，DTI-ALPS指数增加，DMN FC降低，注意力/警觉性、言语学习、视觉学习、社会认知和整体认知得到改善。此外，DTI-ALPS指数增加分别与MDD患者的整体认知改善和DMN FC降低相关。当前研究表明，伏硫西汀可改善MDD患者的类淋巴系统功能和DMN内的脑连接。此外，类淋巴功能的恢复与脑功能和认知的改善有关。：ClinicalTrials.gov标识符：ChiCTR2200057820。
